LENZ Therapeutics, Inc. (LENZ) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 5 Expansion 3 Platform 4 Financial 3

latest quarter score

Earnings Reports

20
LENZ (LENZ) Q2 2026: 45% Prescription Growth Signals Early Commercial Momentum
August 12, 2026
12
Lens Therapeutics (LENZ) Q1 2026: Three-Month Rx Share Hits 66%, Signaling Early Patient Persistence
May 12, 2026
10
LENZ (LENZ) Q4 2025: 45,000 Prescriptions Signal Early Momentum as Presbyopia Category Takes Shape
March 24, 2026
11
Lens Therapeutics (LENZ) Q3 2025: 5,000 Paid Scripts Signal Category-Creating Launch Momentum
November 05, 2025
11
Lens Therapeutics (LENZ) Q1 2025: SG&A Up 19% as LNZ100 Pre-Launch Build Intensifies
July 04, 2025
8
LENZ Therapeutics (LENZ) Q4 2024: $209M Cash Fuels Pre-Launch Momentum for LNZ100
March 19, 2025

Browse all companies